DTIL – precision biosciences, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

DTIL

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/18

07:08 am

dtil

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

High Report

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Report

12/18

07:01 am

dtil

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

High Report

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Report

11/29

04:47 am

dtil

Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More [Yahoo! Finance]

Medium Report

Report

11/21

07:11 am

dtil

Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]

High Report

Precision BioSciences to Participate in Upcoming November Investor Conferences [Yahoo! Finance]

Report

11/21

07:01 am

dtil

Precision BioSciences to Participate in Upcoming November Investor Conferences

High Report

Precision BioSciences to Participate in Upcoming November Investor Conferences

Report

11/15

07:08 am

dtil

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B [Yahoo! Finance]

Medium Report

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B [Yahoo! Finance]

Report

11/15

07:00 am

dtil

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Medium Report

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Report

11/4

07:20 am

dtil

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Medium Report

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Report

11/4

07:18 am

dtil

Precision BioSciences GAAP EPS of -$2.25, revenue of $0.6M [Seeking Alpha]

Medium Report

Precision BioSciences GAAP EPS of -$2.25, revenue of $0.6M [Seeking Alpha]

Report

11/4

07:01 am

dtil

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Medium Report

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Report

11/1

09:45 am

dtil

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? [Yahoo! Finance]

Medium Report

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? [Yahoo! Finance]

Report

10/29

07:01 am

dtil

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Low Report

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Report

10/28

07:10 am

dtil

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 [Yahoo! Finance]

Low Report

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 [Yahoo! Finance]

Report

10/28

07:01 am

dtil

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Low Report

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Report

10/24

04:15 pm

dtil

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Low Report

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Report

10/24

08:50 am

dtil

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Neutral Report

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Report

10/24

08:47 am

dtil

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Low Report

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Report

10/21

07:20 am

dtil

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences [Yahoo! Finance]

Low Report

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences [Yahoo! Finance]

Report

10/21

07:01 am

dtil

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Low Report

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Report

10/16

07:01 am

dtil

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Low Report

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Report

10/3

07:01 am

dtil

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Medium Report

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Report

9/30

07:07 am

dtil

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Medium Report

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Report

9/30

07:01 am

dtil

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Medium Report

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.